TNYA — Tenaya Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1858848 ·
Last close
$0.32
Market Cap
$73.58M
52W High
$1.46
52W Low
$0.30
ADV30
3,424,272
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,697,000 | — | -18,817,000 | -18,938,000 | 76,681,000 | 66,797,000 | 22,164,000 |
| Jun 2026 | 1,110,000 | — | -20,899,000 | -43,393,000 | 93,540,000 | 78,085,000 | 24,131,000 |
| Mar 2026 | 225,000 | — | -20,065,000 | -19,272,000 | 135,070,000 | 80,887,000 | 28,881,000 |
| Dec 2025 | 0 | — | -20,775,000 | -20,175,000 | 146,921,000 | 100,547,000 | 23,656,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-54,410,000
Investing CF
$-211,000
Financing CF
$65,106,000
CapEx
$-263,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.49
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-686,611,000
Inventory
—
Receivables
$573,000
ST Investments
$0
EBIT TTM
$-80,556,000
Pretax Income TTM
$-101,778,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,335,000
EBITDA
$-75,524,000
Free Cash Flow
$-32,600,500
Enterprise Value
$8,806,681
Total Cash
$78,085,000
Total Debt
$3,949,000
Shares Out
227,928,240
Trailing EPS
$-0.48
Book Value
$0.57
ROE
-121.9%
ROA
-47.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -93,331,000 | -90,597,000 | 146,921,000 | 23,656,000 | 123,265,000 | -68,264,000 |
| Dec 2024 | 0 | -115,948,000 | -111,129,000 | 119,940,000 | 27,086,000 | 92,854,000 | -90,501,000 |
| Dec 2023 | 0 | -131,193,000 | -124,084,000 | 170,515,000 | 31,091,000 | 139,424,000 | -102,072,000 |
| Dec 2022 | 0 | -125,621,000 | -123,665,000 | 278,945,000 | 35,569,000 | 243,376,000 | -104,424,000 |
TTM Snapshot
Revenues TTM
$2,567,000
NetIncome TTM
$-103,115,000
OpCashFlow TTM
—
Assets (Latest)
$93,540,000
Forward EPS
$-0.38
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.31 · call volume: 209 · put volume: 40
Expected Move to 2026-12-18:
±$0.20
(65.15%) —
implied range
$0.11 –
$0.51
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CHRS | Coherus Oncology, Inc. | $73.95M | $0.48 | — |
| CLLS | Cellectis S.A. | $77.08M | $1.06 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $68.60M | $0.74 | — |
| ATRA | Atara Biotherapeutics, Inc. | $66.22M | $6.50 | — |
| CRDF | Cardiff Oncology, Inc. | $65.85M | $0.85 | — |
News headlines (Yahoo Finance, 1h cache)
Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 23:45 · Yahoo
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-04 21:05 · Yahoo
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
2026-09-14 12:30 · Yahoo
Treasury yields rise as investors raise bets on Fed rate hike: AlphaCheck
2026-09-10 13:56 · Yahoo
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-03 20:30 · Yahoo
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
2026-08-18 08:01 · Yahoo
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-05 20:05 · Yahoo
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-07-15 01:00 · Yahoo
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
2026-06-29 12:30 · Yahoo
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
2026-05-29 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.